Preview

Современная ревматология

Расширенный поиск

Лечение остеоартроза с точки зрения безопасности фармакотерапии

https://doi.org/10.14412/1996-7012-2009-524

Полный текст:

Аннотация

Показано, что при остеоартрозе (ОА) большое значение имеет применение препаратов гиалуроновой кислоты и «пероральных хондропротекторов», которые оказывают не только симптоматическое, но и структурно-модифицирующее действие. Комбинированная терапия с использованием этих средств позволяет повысить эффективность терапии ОА и снизить угрозу развития лекарственных осложнений благодаря уменьшению потребности в нестероидных противовоспалительных препаратах. Представлены данные, показывающие преимущества использования низкомолекулярного препарата гиалуроновой кислоты (Гиалган®) и препарата на основе неомьляемьа соединений авакадо и сои (Пиаскледин®), а также доказательства их эффективности и безопасности.

Об авторе

A E Karateyev



Литература

1. <div><p>Ревматология. Национальное руководство. Под ред. В.А. Насонова, В.А. Насоновой М.: ГЕОТАР-Медиа, 2008.</p><p>Brend K. Diagnosis and nonsurgical management of osteoarthritis. Professional Communictions, Inc 2000</p><p>Лучихина Л.В. Артроз. Ранняя диагностика и патогенетическая терапия. М.: Медицинская энциклопедия, 2001;167 с.</p><p>Zhang W., Doherty M., Arden N. et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64(4):655-66.</p><p>Jordan K., Arden N., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62(12):1145-55.</p><p>Bonnet C. et al. Osteohondral angiogenesis and synovial inflammation are features of osteoarthritis and may contribute to the severety of cartilage changes. Rheumatology 2005;46:4.</p><p>Denoeud L. et al. First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence. Ann Rheum Dis 2005;64:70-4.</p><p>Schnitzer T., Weaver A., Polis A. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 2005;32:1093-105.</p><p>Pincus T., Koch G., Lei H. et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9.</p><p>Boureau F., Schneid H., Zeghari N. et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis 2004;63:1028-35.</p><p>Parr D., Darekar B., Fletcher A. et al. Joint pain and quality of life: results of a randomized trial. Br J Clin Pharmacol 1989;27:235-42.</p><p>Pavelka K., Peliskovа Z., Stehlikova H. et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig 1998;16(6): 421-9.</p><p>Beaulieu A., Peloso P., Haraoui B. et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: A randomized controlled trial. Pain Res Manag 2008;13(2):103-10.</p><p>Alvarez-Soria M.A., Largo R., Santillana J. et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006;65(8):998-1005.</p><p>Emery P., Koncz T., Pan S. et al. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multi-center, randomized, double-blind, parallel-group, double-dummy, noninferiority study Clin Ther 2008;30(1):70-83.</p><p>Lee T., Bartle B., Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007;120(1):98.</p><p>Fries J., Kristen N., Bennet M. et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.</p><p>Singh G. Recent consideration in nonsteroidal anti-inflammatory drug gastropathy Am J Med 1998;105:31-8.</p><p>Lipworth L., Friis S., Blot W.J. et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 2004;11:156-163.</p><p>Сороцкая В.Н., Каратеев А.Е. Желудочно-кишечные осложнения как одна из причин смерти больных ревматическими заболеваниями. Науч-практич ревматол 2005;4:34-8.</p><p>Lain L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary? Rew Gastroenterol Dis 2004;4:33-41.</p><p>Layton D., Hughes K., Harris S. et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003;42(11):1332-41.</p><p>Laine L., White W., Rostom A. et al. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Semin Arthritis Rheum 2008 Jan 3 [Epub ahead of print].</p><p>Pope J., Anderson J.J., Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477-84.</p><p>Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.</p><p>Polonia J., Boaventura I., Gama G. et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995;13(8):925-31.</p><p>Morgan T., Anderson A., Bertram D. et al. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13(11):1161-7.</p><p>Sowers J., White W., Pitt B. et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;Jan 24;165(2):161-8.</p><p>Aw T.-J., Haas S., Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165: 490-6.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;18;368(9549):1771-81.</p><p>Wang P. et al. Hypertension 2005;46:273.</p><p>Bellamy N., Campbell J., Robinson V. et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;Apr 19;(2):CD005328.</p><p>Lajeunesse D., Delalandre A., Martel-Pelletier J. et al. Hyaluronic acid reverses the abnormal synthetic activity of human osteoarthritic subchondral bone osteoblasts. Bone 2003;33:703-10.</p><p>Moreland L. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003;5:54-67.</p><p>Arrich J., Piribauer F., Mad P. et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005;172 (8).</p><p>Bellamy N., Campbell J., Robinson V. et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;Apr 19;(2):CD005321.</p><p>Altman R., Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998;25(11):2203-12.</p><p>Jubb R., Piva S., Beinat L. et al. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57(6):467-74.</p><p>Jones A., Pattrick M., Doherty S., Doherty M. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage 1995;3(4):269-73.</p><p>Pasquali Ronchetti I., Guerra D., Taparelli F. et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methyl-prednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology (Oxford) 2001;40(2): 158-69.</p><p>Henrotin Y., Deberg M., Crielaard J. et al. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol 2006;33(8):1668-78.</p><p>Henrotin Y., Sanchez C., Deberg M. et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003;30(8):1825-34.</p><p>Mazieres B., Hucher M., Zaim M. et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007;66:639-45.</p><p>Beggee B. et al. Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006;65:222-6.</p><p>Blotman F., Maheu E., Wulwik A. et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 1997;64(12):825-34.</p><p>Maheu E., Mazillres B., Valat J. et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multi-center clinical trial with a six-month treatment period and a two-month follow up demonstrating a persistent effect. Arthritis Rheum 1998;41(1):81-91.</p><p>Appelboom T., Schuermans J., Verbruggen G. et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001;30(4):242-7.</p><p>Lequesne M., Maheu E., Cadet C. et al. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002;47(1):50-8.</p><p>Christensen R., Bartels E., Astrup A. et al. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008;16(4):399-408.</p><p>Walker-Bone K. 'Natural remedies' in the treatment of osteoarthritis. Drugs Aging 2003;20(7):517-26.</p></div><br />


Для цитирования:


Karateyev A.E. Лечение остеоартроза с точки зрения безопасности фармакотерапии. Современная ревматология. 2009;3(1):51-57. https://doi.org/10.14412/1996-7012-2009-524

For citation:


Karateyev A.E. Treating osteoarthrosis in terms of the safety of pharmacotherapy. Modern Rheumatology Journal. 2009;3(1):51-57. (In Russ.) https://doi.org/10.14412/1996-7012-2009-524

Просмотров: 667


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)